Aldeyra Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview

Aldeyra Therapeutics

09/08/2025 24:34

Aldeyra Therapeutics Inc ALDX.OQ ALDX.O is expected to  show a rise in quarterly revenue when it reports  results on November 5 (estimated) for the period ending September 30 2025

The Lexington Massachusetts-based  company is expected to report revenue of $1.083 million, according to the mean estimate from 6 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for Aldeyra Therapeutics Inc is for a loss of 25 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 496.1% in the last three months. ‚Äč

Wall Street's median 12-month price target for Aldeyra Therapeutics Inc is $9.50, about 44.6% above its last closing price of $5.26

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jun. 30 2025
-0.23
-0.24
-0.16
Beat
34.2
Mar. 31 2025
-0.30
-0.28
-0.17
Beat
39.3
Dec. 31 2024
-0.26
-0.23
-0.27
Missed
-19.9‚Äč
Sep. 30 2024
-0.26
-0.25
-0.25
Met
-1.2
‚Äč‚ÄčJun. 30 2024
-0.14
-0.14
-0.28
Missed
-97.5
Mar. 31 2024
-0.10
-0.11
-0.14
Missed
-26.5‚Äč
Dec. 31 2023
-0.05
-0.14
-0.08
Beat
43
Sep. 30 2023
-0.22
-0.24
-0.14
Beat
41.3

This summary was machine generated August 8 at 23:34 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)